RxDoctor Payments Data

Emily Anzmann, DPM

Foot & Ankle Surgery · Des Moines, IANPI 1518341254

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (39.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Arthrex at 39.4% of the total. Reporting peaked in 2019 at $9,229 and has fallen 79.8% since, to $1,866 in 2024.

$14,585in general payments, 2019–2025

Across 107 payments — averaging $136.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$6K
  • Stryker$6K
  • Conetic Solutions, Inc.$1K
  • Treace Medical Concepts, Inc.$1K
  • Smith+Nephew$529
  • Zimmer Biomet$235
  • plus $168 from 1 others

What the payments were for

  • Travel & lodging$4,92834%
  • Food & beverage$3,93527%
  • Education$5,72239%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Arthrex17$5,741
Stryker(2 entities)63$5,556
Conetic Solutions, Inc.2$1,313
Treace Medical Concepts, Inc.6$1,043
Smith+Nephew11$529
Zimmer Biomet6$235
KCI USA, Inc.2$168

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,585 in reported general payments places this provider in the 80th percentile of 112 foot & ankle surgery providers in Iowa.

See all foot & ankle surgery providers in Iowa

Medicare billing

Part B allowed, 2024
$36,375
Medicare patients
150
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.11$3,415
Diclofenac Sodium53$2,483
Terbinafine Hcl73$658
Ciclopirox20$402
Minocycline Hcl23$350
Ketoconazole18$240
Oxycodone Hcl45$227
Ammonium Lactate12$209
Methylprednisolone25$144
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$144
Cephalexin19$99
Meloxicam22$55
Doxycycline Hyclate11$52
Tramadol Hcl11$45
Prednisone18$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$529$3,41511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 foot & ankle surgery providers in Iowa.

Other foot & ankle surgery in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →